Mankind Pharma: FY 2025-26 results, director re-appointment, subsidiary investment
Mankind Pharma · Pharmaceuticals & Biotechnology
Key highlights
- Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, with unmodified opinion from joint statutory auditors.
- Re-appointed Mr. Satish Kumar Sharma as Whole-Time Director for 5 years with effect from September 23, 2026, subject to member approval at the 35th AGM.
- Approved additional investment of up to ₹500 crores in Mankind Medicare Private Limited, a wholly owned subsidiary, in one or more tranches.
Why it's rated major development: the year-on-year change is 91% (50% or more)
Figures checked against the filing by a second AI read, which corrected the first summary. About the business, not the share price.
Original filing
Announcement under Regulation 30 (LODR)-Acquisition
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Aerospace & Defense
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Mankind Pharma
- Financial resultsMajor developmentMankind Pharma: FY26 results, director re-appointment, ₹500 crore subsidiary investment
- Financial resultsMajor developmentMankind Pharma approves Q4 and FY26 results, ₹500 crore subsidiary investment
Other acquisition / merger filings this fortnight
- IndiGrid Infrastructure Trust Q2 FY27 Earnings Conference Call Transcript Released
- Cubical Financial Services Ltd announces promoter reclassification post open offer
- Novus Loyalty Limited approves acquisition of AutoPe Payment Solutions via share swap
- Shish Industries Limited files Composite Scheme of Amalgamation proposal
- Jubilant Ingrevia Limited updates on acquisition of 40% stake in Zettaone Technologies
- NHC Foods approves quarter results, 99.98% Sachmaas Foods investment, two appointments
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.